

Methodology A 33-year-old primiparous female attended at 16 weeks pregnant with vaginal spotting and abnormal cervix on inspection; her smear test had been delayed due to COVID-19. Investigations revealed a stage 2b squamous cell cervical carcinoma. Proposed management options were of pregnancy continuation with neoadjuvant chemotherapy and elective pre-term caesarean section or surgical termination; both followed by chemoradiotherapy.

Results Following fertility counselling, the patient underwent surgical peripartum fetocidal type III nerve sparing radical Wertheim hysterectomy and pelvic lymphadenectomy. Findings were of a 5 cm exophytic tumour with a 3 cm and 5 cm margin of vaginal cuff and parametrium respectively. The couple were subsequently referred on to clinical oncology and for bereavement counselling, mourning the loss of their future fertility over and above that of their unborn baby.

Conclusion Throughout this patient's journey there was not only a host of support including cancer nurse specialist teams; but also in consideration of the clinicians residing over this patient's case. The provision of compassionate care was coupled alongside that of emotionally supporting colleagues within the multidisciplinary team. This case raised significant ethical dilemmas regarding aspects of clinical management with extremely difficult and heartfelt decision-making challenges, which greater emphasised the present loss of life.

2022-RA-1217-ESGO

SUCCOR MORBIDITY. INTRAOPERATIVE AND POSTOPERATIVE COMPLICATIONS IN MINIMALLY INVASIVE VERSUS OPEN RADICAL HYSTERECTOMY IN EARLY CERVICAL CANCER

¹Daniel Vázquez Vicente, ²Felix Boria, ²Teresa Castellanos, ²Mónica Gutiérrez, ³Enrique Chacon, ²Nabil Manzour, ³JA Minguez, ³JL Alcázar, ²Luis Chiva. ¹Gynecology, Clínica Universidad de Navarra, Madrid, Spain; ²Clínica Universidad de Navarra, Madrid, Spain; ³Clínica Universidad de Navarra, Pamplona, Spain

10.1136/ijgc-2022-ESGO.100

Introduction/Background The aim of this study is to compare the incidence of intra and postoperative complications in both approaches.

Methodology We review data from the SUCCOR study (1272 patients with IB1 cervical cancer with a radical hysterectomy performed during 2013–2014). We review the duration of the surgeries, the estimated blood loss, and lengthstay. Regarding intraoperative complications we looked for bleeding, ureteral injury, bladder injury, vascular injury, bowel injury and nerve injury. Regarding postoperative complications we looked for abdominal wall infection, vaginal bleeding, vaginal cuff cellulitis, vaginal cuff dehiscence, fever, postoperative bleeding, bladder dysfunction, urinary infection, hematuria, incontinence, bladder fistula, ureteral fistula, bowel obstruction, pulmonary embolism, pneumonia, pleural effusion, lymphorrhagia and quinous ascites.

Results We noticed that in the MIS compared with abdominal surgery the duration of the surgery was longer (246 vs. 196 minutes) ($p < 0,01$), the estimated blood loss was lower (171 vs 418 mls) ($p < 0,01$) and the lengthstay was shorter (4,7 vs 8,3 days) ($p < 0,01$) We did not find any difference in overall incidence of intraoperative and postoperative complications in the MIS compared with open group. However we found that in the MIS the incidence of vaginal bleeding

(2.9% vs 0.6%); $p < 0,01$, the incidence of vaginal cuff cellulitis (2,9 vs 0,8%); $p < 0,01$ and the vaginal cuff dehiscence were higher than in the open group (3,3 vs 0,5%); ($p < 0,01$). Regarding Grade III clavian dindo complications, in the open group bladder dysfunction (1,3 vs 0,2%) ($p = 0,046$), and abdominal wall infection were higher (1,1 vs 0%) ($p = 0,018$) than in the minimal invasive group. Nevertheless Ureteral fistula was higher in the MIS than in the open group (1,7 vs 0,5%) ($p = 0,037$)

Conclusion We did not find any difference in the overall incidence of intra and postoperative complications in the SUCCOR study when comparing the MIS arm vs open group arm

2022-RA-1219-ESGO

SUCCOR QUALITY: VALIDATION OF ESGO QUALITY INDICATORS FOR SURGICAL TREATMENT OF CERVICAL CANCER

¹Felix Boria, ²Nerea Martin-Calvo, ³Enrique Chacón, ²Arantxa Berasaluce, ⁴Nabil Manzour, ⁵Daniel Vazquez, ⁶Teresa Castellanos, ⁹Luis Chiva. ¹Gynecologic oncology department, Clínica Universidad de Navarra, Madrid, Spain; ²Statistics, Clínica Universidad de Navarra, Pamplona, Spain; ³Gynecologic oncology department, Clínica Universidad de Navarra, Pamplona, Spain; ⁴Gynecologic oncology, Clínica Universidad de Navarra, Pamplona, Spain; ⁵Gynecologic oncology, Clínica Universidad de Navarra, Madrid, Spain; ⁶Gynecologic oncology, Clínica Universidad de Navarra, Madrid, Spain

10.1136/ijgc-2022-ESGO.101

Introduction/Background The main objective of this study was to evaluate the impact in the disease-free survival and risk of relapse of ESGO quality indicators compliance in cervical cancer surgery.

Methodology In this retrospective cohort study 15 ESGO quality indicators were assessed in the succor database (patients who underwent radical hysterectomy for stage IB1 cervical cancer (FIGO 2009)), and the final score ranged between 0 and 16 points. Centers with more than 13 points were classified as high-quality indicator compliance centers. We constructed a weighted cohort using inverse probability weighting to adjust for the variables and using inverse probability weighting. We compared disease-free survival and overall survival using Cox proportional hazards regression analysis in the weighted cohort.

Results A total of 838 patients were included in the study. The mean number of quality indicators compliance in this cohort was 13.6 (SD 1.45). 479 patients were operated in high compliance centers and 359 patients were operated in low compliance centers. Women who were operated on centers with high compliance of quality indicators had significant lower risk of relapse (HR, 0.39; 95% CI, 0.25 to 0.61; $P < 0.001$). The association was slightly reduced but remained significant after further adjustment for surgery related variables – conization, surgical approach and use of manipulator- (HR, 0.48; 95% CI, 0.30 to 0.75; $P = 0.001$) and variables related with clinical evolution- Adjuvant therapy- (HR, 0.47; 95% CI, 0.30 to 0.74; $P = 0.001$). Risk of death from the disease was significantly lower in women operated on in centers with high adherence to quality indicators (HR, 0.42; 95% CI, 0.19 to 0.97; $P = 0.041$). However, the association became no significant after the adjustment for surgery and clinical related variables.

Conclusion Patients with early-stage cervical cancer operated on centers with high compliance of ESGO quality indicators have lower risk of recurrence and death.